MedHub-AI was founded in early 2018 by Or Bruch El with the aim of helping cardiologists deliver better care while simplifying their workflow.
Our technology ensures optimal clinical outcomes by significantly reducing post-procedure adverse events and mortality, preventing unnecessary therapeutic procedures, and additional diagnostic invasive interventions.
We believe that adopting new technologies such as AI and machine learning can enhance the medical field by leading to a more efficient, accurate, and better overall care for every patient.
But it doesn’t end there…
Our Second Why: We believe that excellent care needs to be affordable and accessible for every patient, whether they have health insurance or not.
AutocathFFR™
AutocathFFR™ – an automated decision support system for interventional cardiologists.
The AutocathFFR™ Analysis is the only end-to-end non-invasive diagnostic tool that aids clinicians in quantifying arterial stenosis to determine whether significant narrowing is present. AutocathFFR™ facilitates the selection of the most appropriate, effective, and evidence-based revascularization strategy.
- Rapid, seamless, non-invasive image-based FFR
- Automated stenosis identification and classification
- Real-time stenosis tracking system
- AutocathFFR™ can operate in offline mode
Coming soon:
- AutocathML™, a non-invasive tool providing timely assistance in clinical decision-making for diffuse coronary artery disease and tandem lesions
- AutocathMVD™, the next-gen of microvascular dysfunction assessment
TRY DEMO
Regulatory Status
CE aprroval
AMAR aprroval
Or Bruch El
Chief Executive Officer
Or Bruch El is a Co-founder and CEO of MedHub-AI.
He is responsible for the overall strategy, direction, and vision for MedHub-AI. Or ran over the past 5 years several companies in various sectors such as real-time VR video platform for training of physicians and healthcare providers (VRMS) and a platform for distribution of video contents (Scallopress).
As MedHub-AI’s CEO since 2018 Or has developed close relationships with clinical and business leaders in the cardiology field and leads partnerships and investor relations. He is also an active contributor to MedHub-AI’s science and engineering teams, focusing on automatic medical image analysis.
Or set a goal to sacrifice each moment and effort of his life in order to transform the way we access and receive healthcare. Or is committed to putting all his energy into ensuring optimum benefits to Medhub-AI customers and shareholders.
Yarden Bruch El
COO and Regulatory Affairs
Yarden Bruch El is the COO and Regulatory Affairs Manager of Medhub-AI. Yarden brings more than 5 years of experience in the medical device field as a Quality, Regulatory, and Clinical Affairs Manager. Yarden has vast experience with medical software development and cybersecurity requirements and hands-on experience and knowledge in the complete medical devices regulatory cycle by obtaining worldwide regulatory approvals such as CE, FDA, TGA, and AMAR clearances.
Yarden has completed with distinction her B.Sc degree in Biomedical Engineering at the Ben Gurion University of the Negev. She has served as a head of a technological intelligence research team at the research division of the IDF Intelligence Force, following the graduation of prestige course at 8200 unit.
Prof. Ron Waksman
Ron Waksman, MD, specializes in Interventional Cardiology. Dr. Waksman is the associate director of the Division of Cardiology at MedStar Heart Institute. He is also the director of Cardiovascular Research and Advanced Education at the Heart Institute. In addition, Dr. Waksman serves as a clinical professor of Medicine (Cardiology) at Georgetown University.
He is editor-in-chief of Cardiovascular Revascularization Medicine and on the editorial boards of several other publications, including the European Heart Journal and Journal of Interventional Cardiology.
Dr. Waksman publishes extensively and has authored or co-authored more than 600 articles. He has been the principal investigator for more than 100 research trials. Dr. Waksman serves on the Cardiac Cath Laboratory Peer Review Committee at MedStar Washington Hospital Center and is a MedStar Heart Institute board member.
Prof. Ariel Roguin
Director Hillel Yaffe Medical Center’s Cardiology Division held research and interventional cardiology fellowship at Johns Hopkins Medical Center in Baltimore, USA. Prof. Roguin also holds a Ph.D. in medicine (angiogenesis) and he is an expert in the treatment of stenosis and obstruction of the coronary arteries. He focuses particularly on high-risk patients and during a heart attack. He has published over 200 academic articles. In recent years, he served as Director of the Invasive Cardiology Unit at Rambam Medical Center in Haifa.
Dr. Eyal Ben Assa
Dr. Eyal Ben-Assa is an accomplished Interventional Cardiologist and the Director of Valvular and Structural Heart Disease Services at the Assuta Ashdod Medical Center. He received his medical degree from the Hebrew University of Jerusalem and completed his residency in internal medicine and fellowship in cardiology at the Tel Aviv Medical Center. Dr. Ben-Assa also conducted post-doctoral research on heart valve mechanics at MIT and completed advanced training in Interventional Cardiology and Structural Heart Disease Interventions at MGH, affiliated with Harvard University. With his extensive experience and expertise in Interventional Cardiology,
Mr. Natanel Davidovits
Natanel is a seasoned algorithm & AI researcher, with over 10 years of industry experience. His expertise includes bottom-up R&D of innovative large-scale projects of classical and deep-learning computer-vision, natural-language-understanding, recommendation-systems, data-science, multi-physical systems modeling, and optimization. Before joining MedHub-AI, Natanel had led early-stage startup teams through initial research up to innovative enterprise solutions, for tomorrow’s advances in AI.
Mr. Junichi Osawa
Mr. Junichi Osawa possesses over 40 years of experience in the healthcare industry, with a significant portion of his tenure based in Japan. Within the past two decades, he has specialized in the interventional cardiovascular segment.
In his esteemed roles as President of both VOLCANO Japan and ACIST Japan, Mr. Osawa was instrumental in initiating and establishing direct sales and service operations for IVUS and FFR/CFR products. Under his guidance, these organizations developed an industry-leading sales team. He has a meticulous record of overseeing regulatory processes, ensuring compliance, and formulating commercial processes. This includes creating a distribution logistics infrastructure for disposable sales in consignment and imaging system sales.
One of his notable achievements includes leading the first launch of iFR, a non-hyperemic FFR, in Japan. This success was facilitated by his deep relationships with Key Opinion Leaders (KOLs). Concurrently with his role at ACIST Japan, Mr. Osawa held the position of President at Bracco-Eisai in the pharmaceutical sector, concentrating on Bracco’s CT and MRI contrast agents. His expertise also extends to a directorial role at MEDTRONIC Japan’s Cardiovascular Business Unit, overseeing a range of products such as DES, GC, BC, Distal Protection Devices, and Stent Grafts.
Prior to these appointments, Mr. Osawa committed 20 years to the diagnostic imaging sector. He held the position of Vice President for Global Ultrasound Business at GE HEALTHCARE (previously GE Medical Systems) serving the Asia-Pacific Region. During this period, he also played a pivotal role in GE’s four medical joint ventures across Japan, Korea, China, and India, collaborating closely with local partners as a dedicated member of the Board of Directors. Furthermore, as the Director of CT Business for GE, Mr. Osawa managed worldwide product planning, development, and marketing initiatives, spanning both Radiology and Neurosurgery segments.
Dr. Bruce Samuels
Dr. Bruce A. Samuels, MD, is a staff cardiologist at Cedars-Sinai Medical Center and an Assistant Clinical Professor of Medicine at UCLA’s David Geffen School of Medicine. His clinical and research interests encompass coronary imaging in diabetics, lipid-lowering therapies, coronary angiography, and echocardiography. Dr. Samuels has significantly contributed to the advancement of cardiovascular physiology research and development and is passionate about using AI in physiology as a non-invasive surrogate to replace conventional invasive procedures.